The Effectiveness of Individualised Bone Density Feedback and Osteoporosis Education in Premenopausal Women
Launched by MENZIES INSTITUTE FOR MEDICAL RESEARCH · Jan 5, 2006
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
Fractures due to osteoporosis are a major public health problem. Bone density is one of the major predictors of these osteoporotic fractures and is the result of the amount of bone gained in early life (i.e peak bone mass) and subsequent bone loss. Cigarette smoking, physical inactivity and inadequate calcium intake are widely regarded as risk factors for osteoporosis (as well as for other common diseases for the former two). Despite this information being widely available and actively promoted, the prevalence of these risk factors in the population remains unacceptably high. In women (mean...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • women aged between 25 and 44 years of age
- Exclusion Criteria:
- • previous had measurement of bone densitometry
- • thyroid disease
- • renal failure
- • malignancy
- • rheumatoid arthritis
- • history of hysterectomy
- • hormone replacement therapy
- • were pregnant or planning pregnancy within 2 years of study entry
- • lactating.
About Menzies Institute For Medical Research
The Menzies Institute for Medical Research is a leading research organization dedicated to advancing health outcomes through innovative medical research and clinical trials. Located in Tasmania, Australia, the Institute focuses on a diverse range of health issues, including chronic diseases, mental health, and public health challenges. By fostering collaboration among researchers, clinicians, and community stakeholders, the Menzies Institute aims to translate scientific discoveries into practical applications that improve patient care and promote healthier communities. With a commitment to excellence and ethical standards, the Institute plays a pivotal role in contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hobart, Tasmania, Australia
Patients applied
Trial Officials
Graeme Jones, MD
Principal Investigator
Menzies Institute for Medical Research
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials